Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WST
WST logo

WST Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy West Pharmaceutical Services Inc (WST) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
356.080
1 Day change
-0.44%
52 Week Range
367.660
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

West Pharmaceutical Services Inc (WST) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong bullish momentum with hedge funds significantly increasing their positions, positive analyst upgrades, and a favorable long-term growth outlook in the injectables market. Despite the lack of recent news or Congress trading data, the technical indicators and options sentiment align with a positive investment opportunity.

Technical Analysis

The stock is showing bullish momentum with moving averages in a positive alignment (SMA_5 > SMA_20 > SMA_200). The RSI is neutral at 55.599, and the MACD is below zero but negatively expanding. The stock closed above its pivot level (324.848) and is near its first resistance level (334.875), suggesting potential for further upward movement.

Options Data

Neutral
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
8

Positive Catalysts

  • Hedge funds have increased their buying by 196.32% over the last quarter.

  • Analysts have upgraded the stock with increased price targets, citing strong growth in high-value products and injectables.

  • The stock has an 80% chance of gaining 3.25% in the next day and 2.18% in the next week.

Neutral/Negative Catalysts

  • MACD is negatively expanding, which could indicate short-term bearish pressure.

  • No recent news or Congress trading data to provide additional sentiment insights.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have been upgrading the stock consistently. Wolfe Research upgraded to Outperform with a $375 price target, and Citi raised its price target to $400. Analysts highlight strong Q1 performance and long-term growth potential in injectables.

Wall Street analysts forecast WST stock price to fall
12 Analyst Rating
Wall Street analysts forecast WST stock price to fall
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 357.640
sliders
Low
285
Averages
348.7
High
375
Current: 357.640
sliders
Low
285
Averages
348.7
High
375
Evercore ISI
Daniel Markowitz
Outperform
maintain
$390 -> $410
AI Analysis
2026-07-06
New
Reason
Evercore ISI
Daniel Markowitz
Price Target
$390 -> $410
AI Analysis
2026-07-06
New
maintain
Outperform
Reason
Evercore ISI analyst Daniel Markowitz raised the firm's price target on West Pharmaceutical to $410 from $390 and keeps an Outperform rating on the shares. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector, the analyst tells investors in a research note.
KeyBanc
NULL
to
Overweight
maintain
$350 -> $390
2026-07-02
Reason
KeyBanc
Price Target
$350 -> $390
2026-07-02
maintain
NULL
to
Overweight
Reason
KeyBanc raised the firm's price target on West Pharmaceutical to $390 from $350 and keeps an Overweight rating on the shares. The firm cites increased confidence in West Pharmaceutical benefiting from GLP-1 volumes and improving market conditions.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WST
Unlock Now

People Also Watch